Corporate News

Concepta plc (AIM:CPT), the UK healthcare company targeting the personalised mobile health market with a primary focus on women's fertility, is pleased to announce that it will be exhibiting at the UK Investor Show on 1 April 2017 at the Queen Elizabeth II Conference Centre in Westminster, London.

Concepta's Chairman, Adam Reynolds and CEO, Erik Henau will be presenting and will be available to speak to investors at the event at stand 72.

Erik Henau, CEO of Concepta said: "We are delighted to be attending the UK Investor show this year. It presents us with a fantastic opportunity to meet with current and future shareholders and we look forward to updating them on the Company's progress."

More information on the event can be found at www.ukinvestorshow.com 

Enquiries:

Concepta plc

Adam Reynolds, Chairman

Tel: +44 (0) 7785 908158

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin / Mark Brady

Tel: +44 (0)20 368 3550

Beaufort Securities Limited (Broker)

Jon Belliss

Tel: +44 (0)20 7382 8300

Yellow Jersey PR Limited (Financial PR)

Felicity Winkles / Joe Burgess / Francesca Hillier

Tel: +44 (0) 7748 843 871

About Concepta Plc:

Concepta plc is a pioneering UK healthcare company that has developed a proprietary platform and products targeted at the personalised mobile health market with a primary focus on women's fertility and specifically unexplained infertility*.

Founded in 2013, Concepta has developed a revolutionary flagship product 'myLotus' for home self-testing that helps women with unexplained infertility to conceive.  

myLotus is the only consumer product which allows both quantitative and qualitative measurements of a woman's personal hCG and LH hormone levels in an easy to use home test to facilitate higher conception rates and early diagnosis of any fertility problems.  Competitor products currently only allow qualitative measurement and are based on the 'average woman'.  

Concepta has a defined route to market for its new 'myLotus' product with Regulatory approvals for launch in China in place for H1 2017 and CE-Marking for UK and Europe to follow later in 2017, where the revenue potential of the Chinese and EU infertility market is worth c.£600m per annum for the company.

*Unexplained infertility refers to women that have been unable to conceive after 6 months of trying. This highly motivated target group of consumers won't typically be offered medical intervention until 12 months of unsuccessfully trying, with IVF not offered until two years. Research indicates couples start to take positive action ahead of this time and there is little medical support to help them do so.